You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity ...

The rise in GLP-1 use among young women raises concerns about contraceptive efficacy and potential pregnancy risks. Learn ...

When it came to cardiovascular incidents, the report showed major gains for GLP-1 users, too. 44% experienced fewer ...

More and more companies are investing in developing GLP-1R agonists, including dual and triple agonists and combination ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on more ...

Full Frame Growth Partners is a minority investor in California-based Supergut, a company making powdered supplements and ...

Weightloss drugs can also cause what is known as Ozempic hands. As with the feet and face, these areas show fat loss more ...

Bariatric surgery and GLP-1s conferred similar outcomes in mortality, adverse cardiovascular events and cirrhosis development ...

The use of GLP-1s among patients with type 2 diabetes appeared associated with significantly reduced risk for certain ...

Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...